DNTH
Dianthus Therapeutics Inc.
NASDAQ: DNTH · HEALTHCARE · BIOTECHNOLOGY
$87.12
+0.47% today
Updated 2026-05-11
Market cap
$4.67B
P/E ratio
—
P/S ratio
3,497.25x
EPS (TTM)
$-4.23
Dividend yield
—
52W range
$17 – $97
Volume
1.0M
Dianthus Therapeutics Inc. (DNTH) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-39.5%
Last 4 quarters
Revenue YoY growth
-60.2%
Most recent quarter
EPS YoY growth
-3.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+10.4%
Last 4 reports
Positive reaction rate
75%
3 of 4 quarters
Largest single-day move
+33.3%
2026-03-09
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-31 | $-0.85 | +22.9% | $79.45 | $84.56 | +6.4% |
| 2026-03-09 | $-1.43 | -38.6% | $65.20 | $86.92 | +33.3% |
| 2025-11-05 | $-0.97 | -76.4% | $33.20 | $36.43 | +9.7% |
| 2025-08-07 | $-0.88 | -66.0% | $20.39 | $18.76 | -8.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $-1.10 | $-0.85 | +22.9% | $463000.00 | -60.2% |
| 2025-12-31 | $-1.03 | $-1.43 | -38.6% | $284000.00 | -78.6% |
| 2025-09-30 | $-0.55 | $-0.97 | -76.4% | $396000.00 | -81.8% |
| 2025-06-30 | $-0.53 | $-0.88 | -66.0% | $193000.00 | -89.6% |
| 2025-03-31 | $-0.71 | $-0.82 | -15.5% | $1.16M | +33.1% |
| 2024-12-31 | $-0.76 | $-0.81 | -6.6% | $1.33M | +190.2% |
| 2024-09-30 | $-0.59 | $-0.72 | -22.0% | $2.17M | +135.1% |
| 2024-06-30 | $-0.55 | $-0.51 | +7.3% | $1.86M | — |
| 2024-03-31 | $-0.44 | $-0.54 | -22.7% | $874000.00 | — |
| 2023-12-31 | $-1.01 | $-0.71 | +29.7% | $457000.00 | — |
| 2023-09-30 | $-0.56 | $-3.78 | -575.0% | $924000.00 | — |
Frequently asked questions
Has Dianthus Therapeutics Inc. beaten earnings estimates?
Dianthus Therapeutics Inc. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -39.5% over the last 4 quarters.
How does DNTH stock react to earnings?
DNTH stock has moved an average of +10.4% in the trading day following earnings over its last 4 reports, with positive reactions in 75% of those quarters.
What is Dianthus Therapeutics Inc.'s revenue growth rate?
Dianthus Therapeutics Inc. reported year-over-year revenue growth of -60.2% in its most recent quarter, with EPS growing -3.7% year-over-year.